Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 9001-9010 Newer>

Chemistry World December 5, 2014 Rebecca Trager	Tufts' $2.6bn drug development figure questioned Recent data indicating that it costs about $2.6 billion to develop and win market approval for a new prescription drug in the US has come under scrutiny.
Chemistry World December 5, 2014 Andy Extance	GSK cuts US jobs in push for savings 350 of the chemists, engineers and other roles will be lost by April 2015, another 450 by July, and the remainder eliminated by the end of the year.
Chemistry World December 4, 2014 Phillip Broadwith	Otsuka to buy neurology specialist Avanir Japanese firm Otsuka has agreed to buy US neurological drug specialist Avanir for $3.5 billion in cash.
Chemistry World December 4, 2014 Anthony King	Cystic Fibrosis Foundation sells drug royalty rights for $3.3bn The Cystic Fibrosis Foundation has sold royalty rights to treatments developed with support from its 'venture philanthropy' model.
Chemistry World December 3, 2014 Maria Burke	Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
Chemistry World November 26, 2014 Phillip Broadwith	UCB sells speciality generics subsidiary Belgian drugmaker UCB has agreed to sell its specialty generics subsidiary, Kremers Urban, to private equity firms Advent International and Avista Capital Partners for $1.5 billion
Chemistry World November 24, 2014 Andy Extance	Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis.
Chemistry World November 21, 2014 Rebecca Trager	Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs
Chemistry World November 20, 2014 Rebecca Trager	US drug development costs surge Developing and winning market approval for a new prescription drug in the US takes about a decade and costs approximately $2.6 billion, according to data released by Tufts University researchers.
<Older 9001-9010 Newer> Return to current articles.